Peptide compound, composition and use thereof
Through solid-phase synthesis and in vitro biological test screening, polypeptide compounds with antioxidant and anti-photoaging effects were obtained, which solved the problem of skin aging caused by photoaging and achieved significant anti-photoaging and whitening effects. It is suitable for drugs and skin care products. Application.
Patent Information
- Application Number
- PCT/CN2024/091638
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-21
AI Technical Summary
The prior art is difficult to effectively solve the problem of skin aging caused by photoaging, especially the problems of skin damage and wrinkles, pigmentation, dryness, etc. by ultraviolet radiation, and the existing polypeptide molecules have limited application in antioxidant.
A small polypeptide molecule with a specific amino acid sequence was obtained through solid phase synthesis, which had antioxidant activity and anti-photoaging effects, and polypeptide compounds that significantly inhibit ROS release, tyrosinase activity and apoptosis were screened through in vitro biological tests. Polypeptide compounds that significantly inhibit ROS release, tyrosinase activity and cell apoptosis were screened through in vitro biological tests. , used to prepare drugs and skin care products with anti-photoaging and whitening effects.
It has achieved significant inhibition of ROS release, tyrosinase activity and cell apoptosis, promoted collagen production, and has potential anti-photoaging, antioxidant and whitening effects. It is suitable for the preparation of anti-photoaging drugs and skin care products.
Smart Images

Figure PCTCN2024091638-FTAPPB-I100001 
Figure PCTCN2024091638-FTAPPB-I100002 
Figure PCTCN2024091638-FTAPPB-I100003
Abstract
Description
Peptide compound, composition and application thereof
[0001] This application claims priority to the Chinese patent application filed with the China Patent Office on May 16, 2023, with application number 202310560347.0 and invention name “A peptide compound, composition and its application”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present invention belongs to the technical field of polypeptide synthesis, and in particular relates to a peptide compound with anti-photoaging and whitening effects, a composition and applications thereof. Background Art
[0003] According to data released by the China Flavor and Fragrance Cosmetic Industry Association, the most popular services and projects that women are most concerned about are: anti-aging care, freckle removal, and whitening; among them, the mention rate of anti-aging reached 72.2%. From the basic attributes of the anti-aging consumer group, it can be seen that the current consumer group is mainly female, accounting for as high as 72%; from the age of the consumer group, the proportion of people aged 31-40 is the most prominent, followed by 24-30 years old, and the concept of anti-aging is gradually becoming younger. As the concept of anti-aging gradually becomes younger, the age structure of anti-aging consumers extends to both ends, and the demand for combating different levels of aging symptoms will continue to grow. Skin aging refers to the physiological phenomenon in which the cell structure and function of skin tissue degenerate under the continuous influence of internal and external environments, resulting in changes in skin texture (such as elasticity, tension, etc.), pigmentation changes, and blood vessel atrophy or hyperplasia. It is usually divided into endogenous aging (natural aging) and exogenous aging (photoaging, etc.).
[0004] The effects of sunlight on the skin are profound and are thought to account for 90% of exogenous skin aging. Periodic and continuous exposure to ultraviolet (UV) radiation is a classic and key factor in skin aging, known as photoaging. Photoaging is characterized by wrinkles, inflammation, hyperpigmentation, sagging, and dryness. Although UVB accounts for only a small portion of total UV radiation, it is most active in damaging the epidermis and dermis of the skin. Some studies have reported that UVB irradiation increases intracellular reactive oxygen species (ROS), such as superoxide anions, hydroxyl radicals, and hydrogen peroxide. ROS stimulate various signaling pathways and initiate biological processes, including cell death, cell senescence, and inflammation. It has been reported that peptide molecules from natural sources have antioxidant effects and are used in skin care and treatment, which provides a possibility for the development of peptide molecules for anti-photoaging.
[0005] Summary of the Invention
[0006] Based on the above background, the present invention obtained a small polypeptide molecule represented by general formula I through solid-phase synthesis, and the inventors screened and obtained polypeptides with antioxidant activity, anti-photoaging, whitening and other effects through in vitro biological testing, filling and expanding the application prospects of polypeptide molecules in anti-photoaging.
[0007] In a first aspect, the present invention provides a peptide compound, and a pharmaceutically acceptable salt, stereoisomer, and solvate thereof, characterized in that the amino acid sequence of the peptide compound is selected from one of the following:
[0008] (1) the amino acid sequence of formula I: XX1-XX2-XX3-XX4-XX5-XX6-XX7-XX8-XX9-XX10 (I);
[0009] (2) differs from the amino acid sequence of Formula I by no more than 5, 4, 3, 2, or 1 amino acid;
[0010] (3) a sequence having at least 80% identity to the amino acid sequence of Formula I;
[0011] (4) is a variant of the amino acid sequence shown in Formula I, wherein the difference between the variant and the amino acid sequence shown in Formula I includes substitution, deletion and / or insertion of one or more amino acid residues or at least one N- / C-terminal extension.
[0012] In the amino acid sequence shown in Formula I,
[0013] XX1 is selected from Tyr, Phe, Trp, D-Tyr, D-Trp or D-Phe;
[0014] XX2 is selected from Leu, He, Gly, Aib, Met, Ala, Pro, D-Pro, D-Leu, D-He, D-Gly, D-Met or D-Ala;
[0015] XX3 is selected from Ser, Thr, Cys, D-Ser, D-Thr or D-Cys;
[0016] XX4 is selected from Ser, Thr, Cys, D-Ser, D-Thr or D-Cys;
[0017] XX5 is selected from Leu, He, Gly, Aib, Met, Ala, Pro, D-Pro, D-Leu, D-He, D-Gly, D-Met or D-Ala;
[0018] XX6 is selected from Asp, Asn, Glu, Gln, D-Asp, D-Asn, D-Glu or D-Gln;
[0019] XX7 is selected from Leu, He, Gly, Aib, Met, Ala, Pro, D-Pro, D-Leu, D-He, D-Gly, D-Met or D-Ala;
[0020] XX8 is selected from Cys, Met, D-Cys or D-Met;
[0021] XX9 is selected from Leu, He, Gly, Aib, Met, Ala, Pro, D-Pro, D-Leu, D-He, D-Gly, D-Met or D-Ala;
[0022] XX10 is selected from Cys, Met, D-Cys or D-Met.
[0023] More preferably, in the amino acid sequence shown in Formula I,
[0024] XX1 is selected from Phe, Trp, D-Trp or D-Phe;
[0025] XX2 is selected from Leu, Ile, D-Leu or D-Ile;
[0026] XX3 is selected from Ser, Cys, D-Ser or D-Cys;
[0027] XX4 is selected from Thr, Cys, D-Thr or D-Cys;
[0028] XX5 is available in Pro or D-Pro;
[0029] XX6 is selected from Glu, Asp, D-Asp or D-Glu;
[0030] XX7 is selected from Gly, Pro, D-Pro or D-Gly;
[0031] XX8 is selected from Cys, Met, D-Cys or D-Met;
[0032] XX9 is selected from Ala, Pro, D-Pro or D-Ala;
[0033] XX10 is selected from Cys, Met, D-Cys or D-Met.
[0034] Preferably, the amino acid sequence of the peptide compound represented by Formula I is as shown in Molecule 1:
[0035] Molecule 1: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2.
[0036] Further preferably, the peptide compounds of the present invention include molecule 1 and a peptide compound having no more than two amino acid differences from molecule 1, molecule 1: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2. The "difference" includes substitution, deletion, or insertion.
[0037] Preferably, the peptide compound XX1 has an amino group at its end, or the amino group forms an amide bond with an acetyl group, a formyl group or a methylsulfonyl group.
[0038] Preferably, the XX10 end of the peptide compound is a carboxyl group, or the carboxyl group is condensed with an amine compound to form an amide bond, and the amine compound includes but is not limited to NH3, MeNH2, Me2NH, EtNH2, and Et2NH.
[0039] Preferably, the amino group of the amino acid in the peptide compound may be substituted by a C1-C4 alkyl group, and the C1-C4 alkyl group is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
[0040] In a preferred embodiment of the present invention, the peptide compounds are molecules 1 to 32, the amino acid sequences are shown in SEQ ID NOs: 1 to 32, and the specific structures are as follows:
[0041] Molecule 1: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0042] Molecule 2: H-Phe-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0043] Molecule 3: H-Trp-Ile-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0044] Molecule 4: H-Trp-Leu-Cys-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0045] Molecule 5: H-Trp-Leu-Ser-Cys-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0046] Molecule 6: H-Trp-Leu-Ser-Thr-Pro-Asp-Pro-Met-Pro-Met-NH2;
[0047] Molecule 7: H-Trp-Leu-Ser-Thr-Pro-Glu-Gly-Met-Pro-Met-NH2;
[0048] Molecule 8: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Cys-Pro-Met-NH2;
[0049] Molecule 9: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Ala-Met-NH2;
[0050] Molecule 10: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Cys-NH2;
[0051] Molecule 11: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH;
[0052] Molecule 12: H-Phe-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH;
[0053] Molecule 13: H-Trp-Ile-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH;
[0054] Molecule 14: H-Trp-Leu-Cys-Thr-Pro-Glu-Pro-Met-Pro-Met-OH;
[0055] Molecule 15: H-Trp-Leu-Ser-Cvs-Pro-Glu-Pro-Met-Pro-Met-OH;
[0056] Molecule 16: H-Trp-Leu-Ser-Thr-Pro-Asp-Pro-Met-Pro-Met-OH;
[0057] Molecule 17: H-Trp-Leu-Ser-Thr-Pro-Glu-Gly-Met-Pro-Met-OH;
[0058] Molecule 18: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Cys-Pro-Met-OH;
[0059] Molecule 19: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Ala-Met-OH;
[0060] Molecule 20: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Cys-OH;
[0061] Molecule 21: HD-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0062] Molecule 22: H-Trp-Aib-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0063] Molecule 23: H-Trp-Leu-Ser-Thr-Aib-Glu-Pro-Met-Pto-Met-NH2;
[0064] Molecule 24: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Aib-Met-NH2;
[0065] Molecule 25: H-Trp-Met-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0066] Molecule 26: H-Trp-Ala-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0067] Molecule 27: H-Tyr-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0068] Molecule 28: H-Trp-Gly-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2;
[0069] Molecule 29: H-Trp-Met-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH;
[0070] Molecule 30: H-Trp-Ala-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH;
[0071] Molecule 31: H-Tyr-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH;
[0072] Molecule 32: H-Trp-Gly-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH.
[0073] In the above structure, -H represents the amino end, -NH2 represents the formation of an amide bond, and -OH represents the carboxyl end.
[0074] In a second aspect, the present invention provides a composition comprising a peptide compound having the above-mentioned amino acid sequence, and pharmaceutically acceptable salts, stereoisomers, and solvates thereof.
[0075] Preferably, the composition further comprises pharmaceutically acceptable excipients, including but not limited to adhesives, suspending agents, emulsifiers, diluents, fillers, adhesives, disintegrants, lubricants, wetting agents, chelating agents, preservatives, and flavoring agents.
[0076] In a third aspect, the present invention provides the above-mentioned peptide compound, and its pharmaceutically acceptable salts, stereoisomers, and solvates, and the use of the above-mentioned composition in the preparation of medicines and / or cosmetics, wherein the medicines and / or cosmetics have at least one of the following effects: whitening, inhibiting melanin production, removing spots, fading spots, anti-wrinkle, anti-aging, anti-photoaging, moisturizing, anti-inflammatory, antioxidant, tissue regeneration and repair after skin photodamage, promoting collagen synthesis, cell repair, and promoting cell adhesion.
[0077] The peptide compounds provided by the present invention are active peptides synthesized in solid phase, and have the advantages of good stability, weak cytotoxicity, and easy preparation. The peptide compounds provided by the present invention are added to cell culture medium, and the amount of ROS released by cells irradiated by UVB after polypeptide treatment is measured. The results show that the polypeptides all show the ability to significantly inhibit ROS release, indicating that the polypeptide compounds provided by the present invention have potential anti-photoaging efficacy. The polypeptides provided by the present invention have the effect of significantly inhibiting tyrosinase activity and have potential whitening efficacy. The polypeptides provided by the present invention have the effect of inhibiting cell apoptosis. The polypeptides provided by the present invention have the effect of promoting the production of collagen I, collagen type III and fibronectin. Therefore, the peptide compounds provided by the present invention have anti-photoaging, antioxidant, anti-aging and whitening effects, and have great application prospects in the preparation of drugs and / or skin care products with anti-photoaging efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1 HPLC profile of molecule 1 polypeptide compound;
[0079] Figure 2 HPLC profile of polypeptide compound 11;
[0080] Figure 3 Statistical graph of the tyrosinase activity inhibition results of peptides 1 to 16;
[0081] Figure 4 is a statistical diagram of the results of tyrosinase inhibition by peptides 17 to 32;
[0082] Figure 5 Statistical graph of the results of ROS release inhibition by peptides 1 to 16;
[0083] Figure 6 Statistical graph of the results of the inhibition of ROS release by peptides 17 to 32;
[0084] Figure 7 Statistical diagram of the inhibitory effect of different concentrations of molecule 1 on ROS release;
[0085] Figure 8: Cell imaging of the anti-apoptotic effect of peptide molecule 1;
[0086] Figure 9 is a statistical diagram of the anti-apoptotic results of polypeptide molecule 1;
[0087] Figure 10: Cellular imaging of molecule 1 polypeptide reducing type I collagen loss;
[0088] Figure 11 Statistical graph of how polypeptide molecule 1 reduces type I collagen loss;
[0089] Figure 12: Cellular imaging of molecule 1 polypeptide reducing type III collagen loss;
[0090] Figure 13 Statistical graph showing how polypeptide molecule 1 reduces type III collagen loss;
[0091] Figure 14: Cellular imaging of molecule 1 polypeptide reducing fibronectin loss;
[0092] Figure 15 is a statistical graph showing how polypeptide molecule 1 reduces fibronectin loss;
[0093] Figure 16: Microscopic imaging analysis of the effect of molecule 1 polypeptide on the tail fin of juvenile fish. DETAILED DESCRIPTION
[0094] The following is a clear and complete description of the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts are within the scope of protection of the present invention.
[0095] Synthesis of polypeptide compounds
[0096] Example 1 Molecule 1 H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2
[0097] Step 1: Synthesis of Fmoc-Met-resin 1
[0098] Removal of the Fmoc protecting group: Rink Amide MBHA Resin (0.58 mmol / g, 1.723 g) was swollen in DCM (20 mL) in a peptide synthesis tube at room temperature for 15 minutes. The solvent was drained, and piperidine / DMF (1 / 4 by volume, 20 mL) was added. The reaction was allowed to react at room temperature for 5 minutes. The mixture was then drained, and piperidine / DMF (1 / 4 by volume, 20 mL) was added again and allowed to react at room temperature for 5 minutes. After the reaction was complete, the reaction solution was drained and washed six times with DMF (20 mL). The solution was then drained and prepared for the next reaction.
[0099] Amino acid coupling: HOBT (268 mg, 2 mmol), HBTU (767 mg, 2 mmol), and DIEA (399 mg, 3 mmol) were added to a solution of Fmoc-Met-OH (744 mg, 2 mmol) in DMF (20 ml), and the mixture was activated on ice for 15 min. After activation, the activation solution was added to the prepared resin and reacted at room temperature for 1 h. The reaction solution was drained and the resin was washed six times with DMF (20 mL) to obtain Fmoc-Met-resin 1.
[0100] Repeat the above operation to couple amino acids Fmoc-Pro-OH, Fmoc-Met-OH, Fmoc-Pro-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, and Fmoc-Trp(Boc)-OH one by one to obtain Fmoc-Trp(Boc)-Leu-Ser(tBu)-Thr(tBu)-Pro-Glu(OtBu)-Pro-Met-Pro-Met-resin 1.
[0101] Removal of the Fmoc protecting group: To the resin prepared above was added piperidine / DMF (1 / 4 by volume, 20 mL), the mixture was reacted at room temperature for 5 minutes, drained, and piperidine / DMF (1 / 4 by volume, 20 mL) was added again and the mixture was reacted at room temperature for 5 minutes. After completion of the reaction, the reaction solution was drained and washed six times with DMF (20 mL), then washed twice alternately with DCM (20 mL) and MeOH (20 mL), and finally washed twice with MeOH (20 mL). The resulting resin was dried in a vacuum oven at 30°C for 3 h to obtain H-Trp(Boc)-Leu-Ser(tBu)-Thr(tBu)-Pro-Glu(0tBu)-Pro-Met-Pro-Met-Resin 1 (3.677 g).
[0102] Step 2: Synthesis of H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2 (molecule 1)
[0103] The H-Trp(Boc)-Leu-Ser(tBu)-Thr(tBu)-Pro-Glu(OtBu)-Pro-Met-Pro-Met-resin 1 (3.677 g) prepared above and a mixed solution of TFA:TIS:H2O (volume ratio 95:2.5:2.5, 36 ml) were added to a 100 ml reaction flask and reacted at room temperature for 3 h. After the reaction, the mixture was filtered and washed three times with 10 ml of TFA. The combined solution was concentrated to about 5 ml. The concentrated solution was added dropwise to 50 ml of methyl tert-butyl ether, settled in an ice bath for 30 minutes, centrifuged, and washed three times with methyl tert-butyl ether (30 ml). The solid was placed in a vacuum drying oven and dried overnight to obtain 432 mg of a white solid, which was directly purified by Pre-HPLC to obtain a purified solution, which was concentrated and lyophilized to obtain 7.20 mg of a white solid with a purity of 99.61% (HPLC shown in Figure 1).
[0104] MS (ESI): m / z M+H + =1187.6, (M+2H + ) / 2=594.5,M+Na + =1209.6
[0105] The preparation methods of compounds with an amide at the carbon end (such as molecules 2 to 10) are consistent with the preparation method of molecule 1.
[0106] Example 2 Molecule 11 H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH
[0107] Step 1: Synthesis of Fmoc-Met-resin
[0108] 2-CTC Resin (0.512 g, 0.5 mmol) was swollen with DCM (5 ml) in a peptide synthesis tube at room temperature for 15 minutes. The solvent was drained, and a mixed solution of Fmoc-Met-OH (372 mg, 1 mmol) and DIEA (191 mg, 1.5 mmol) in DCM (5 mL) was added. The mixture was purged with nitrogen at room temperature for 2 hours. After the reaction time was up, 0.5 ml of methanol and 0.3 ml of DIEA were added and the reaction was continued for 15 minutes. The reaction solution was drained, washed three times with DCM (5 mL), and finally washed three times with DMF (5 mL). The solvent was drained to obtain Fmoc-Met-resin, which was used directly in the next reaction.
[0109] Step 2: Synthesis of H-Trp(Boc)-Leu-Ser(tBu)-Thr(tBu)-Pro-Glu(OtBu)-Pro-Met-Pro-Met-resin
[0110] Removal of the Fmoc protecting group: To the Fmoc-Met-resin obtained above, piperidine / DMF (1 / 4 by volume, 5 mL) was added and the mixture was reacted at room temperature for 5 minutes. The mixture was then drained and piperidine / DMF (1 / 4 by volume, 5 mL) was added again and the mixture was reacted at room temperature for 5 minutes. After the reaction was complete, the reaction mixture was drained and washed six times with DMF (5 mL). The mixture was then drained and prepared for the next reaction.
[0111] Coupling of amino acids: HOBT (134 mg, 1 mmol), HBTU (380 mg, 1 mmol), and DIEA (196 mg, 1.5 mmol) were added to a solution of Fmoc-Pro-OH (378 mg, 1 mmol) in DMF (5 ml), and the mixture was activated on ice for 15 min. After activation, the activation solution was added to the resin prepared above and reacted at room temperature for 1 h. The reaction solution was drained and the resin was washed 6 times with DMF (5 mL) to obtain Fmoc-Pro-Met-resin.
[0112] Repeat the above operation to couple amino acids Fmoc-Met-OH, Fmoc-Pro-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, and Fmoc-Trp(Boc)-OH one by one to obtain Fmoc-Trp(Boc)-Leu-Ser(tBu)-Thr(tBu)-Pro-Glu(OtBu)-Pro-Met-Pro-Met-resin.
[0113] Removal of the Fmoc protecting group: To the resin prepared above, piperidine / DMF (1 / 4 by volume, 5 mL) was added, the mixture was reacted at room temperature for 5 minutes, the mixture was drained, and piperidine / DMF (1 / 4 by volume, 5 mL) was added again and the mixture was reacted at room temperature for 5 minutes. After completion of the reaction, the reaction solution was drained and washed six times with DMF (5 mL), then washed twice alternately with DCM (5 mL) and MeOH (5 mL), and finally washed twice with MeOH (5 mL). The resulting resin was dried in a vacuum oven at 30°C for 3 hours to obtain 1.421 g of H-Trp(Boc)-Leu-Ser(tBu)-Thr(tBu)-Pro-Glu(OtBu)-Pro-Met-Pro-Met-resin.
[0114] Step 3: Synthesis of H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH (molecule 11)
[0115] The H-Trp(Boc)-Leu-Ser(tBu)-Thr(tBu)-Pro-Glu(OtBu)-Pro-Met-Pro-Met-resin (1.421 g) prepared above and a mixed solution of TFA:TIS:H2O (volume ratio 95:2.5:2.5, 14 ml) were added to a 50 ml reaction flask and reacted at room temperature for 2 h. After the reaction, the mixture was filtered and washed three times with 5 ml of TFA. The combined solution was concentrated to about 2 ml. The concentrated solution was added dropwise to 40 ml of methyl tert-butyl ether, settled in an ice bath for 30 minutes, centrifuged, and washed three times with methyl tert-butyl ether (10 ml). The solid was placed in a vacuum drying oven and dried overnight to obtain 215 mg of a white solid, which was directly purified by Pre-HPLC to obtain a purified solution, which was concentrated and lyophilized to obtain 15.3 mg of a white solid with a purity of 93.60% (HPLC shown in Figure 2).
[0116] MS (ESI): m / z 594.7 [M / 2+H] + ,1188.5[M+H] +
[0117] The preparation methods of compounds with carboxylic acid at the carbon end (such as molecules 12 to 20) are consistent with the preparation method of molecule 11.
[0118] The compound information of molecules 1-32 prepared in the examples of the present invention is shown in the following table:
[0119] Table 1
[0120] Effect embodiment
[0121] Effect Example 1 Melanin Inhibition Experiment with 1 to 32 Molecules
[0122] B16F10 cells in the logarithmic growth phase were taken and inoculated into a 96-well plate (Costar 3599) to reach 2w cells per well. After culture for 24h, the old culture medium was discarded. 100u1 blank culture medium (1640 basic culture medium Gibco 8121693) was added to the blank control group. The positive drug group was added with a basic culture medium containing 40μM Deoxyarbutin. The other wells were added with a basic culture medium containing molecules 1 to 32, and the compound dose was 40μM. Three replica wells were set up. After incubation for 48h, the cells were digested with 50μL of trypsin digestion solution (penicillin-streptomycin solution (Biosharp-BL505A)) and 50μL of PBS (Biosharp 22305954) and resuspended. The entire 96-well plate was transferred to -80°C. After the cells were frozen, they were thawed at room temperature, repeated three times, and centrifuged at 2500 rpm for 10 min. 40 μL of the supernatant was added to a new 96-well plate, and 40 μL of 9 mM L-DOPA (Solarbio 59-92-7) was added. The absorbance was measured at 450 nm and the reaction was carried out at 37°C for 90 min before detection.
[0123] As shown in Figures 3 and 4, at a concentration of 40 μM, the synthesized polypeptide significantly inhibited tyrosinase activity (P < 0.01), indicating that this type of polypeptide molecule has potential whitening effect.
[0124] Effect Example 2: Anti-photoaging screening experiment of molecules 1 to 32
[0125] Logarithmically growing HaCa T cells were seeded into black-edged, transparent-bottomed well plates to a volume of 2 × 10 cells per well. 4Cells were cultured in a complete culture medium (4.5 ml FBS (Sigma-F8318) + 45 ml MEM basal medium (gibco-C11095500BT) + 0.5 ml penicillin-streptomycin solution (Biosharp-BL505A)) at 37°C in a carbon dioxide incubator with a 5% CO2 concentration for 24 hours. The old culture medium was discarded, and 100 μL of HEPES was added to each well. The plate was moved under the UVB device and irradiated with 45 mJ. The control group (i.e., blank untreated), the Rosup group (chemically induced ROS release reference group), and the model group (UVB irradiation group) were irradiated with the liquid and replaced with blank basal medium. The other wells were added with basal medium containing molecules 1 to 32 (MEM basal medium (gibco-C11095500BT)). The dose of molecules 1 to 32 was 50 μM. Three replicate wells were set up and cultured for 24 hours. 40 minutes before the start of the test, 100 μg / mL of ROSup (solvent DMSO, ROSup: blank culture medium = 1:1000) was added to the Rosup group (chemically induced ROS release reference group) and placed in an incubator for 40 minutes; a 1:1000 dilution of DCFH-DA was pre-prepared, the liquid was discarded, and after loading the probe, the 96-well plate was placed in an incubator and incubated for 40 minutes; washed with PBS 4 times, each time for 3 minutes (low-speed oscillation in an oscillator); after replacing with new PBS, the signal value at 495 nm was detected by an enzyme-labeled instrument. The results are shown in Figures 5 and 6. This type of polypeptide molecule partially has anti-photoaging effects, and then a multi-concentration gradient was performed to evaluate its photoaging effect. The operating steps are the same as above. The dosages of polypeptide molecules are 22 μM, 33 μM, 49 μM, 74 μM, 167 μM, and 250 μM, respectively. The results are shown in Table 2. Compared with L-carnosine, the EC values of some polypeptide molecules are 50 Lower, indicating that the polypeptide has a strong anti-photoaging effect.
[0126] Table 2 Peptide molecules inhibit ROS release EC 50
[0127] Effect Example 3: Anti-light aging verification experiment of molecule 1
[0128] The above experiments have shown that this type of peptide has significant whitening and anti-photoaging effects. We will conduct in-depth research using molecule 1 as an example. Logarithmically growing HaCa T cells were inoculated into a black-edged transparent bottom well plate to reach 3×10 per well. 4The cells were cultured in a complete culture medium (4.5 ml FBS (Sigma-F8318) + 45 ml MEM basal medium (gibco-C11095500BT) + 0.5 ml penicillin-streptomycin solution (Biosharp-BL505A)) in a carbon dioxide incubator at 37°C and 5% CO2 for 24 hours. The old culture medium was discarded, 100 μL of PBS was added to each well, and the plate was moved under the UVB device and irradiated with 105 mJ. The liquid was discarded and replaced with blank basal medium in the Contr01 group (i.e., blank untreated) and the model group (UVB irradiation group). The other wells were added with basal medium containing molecule 1 (MEM basal medium (gibco-C11095500BT)) at a concentration of 50 μM to 0.0122 μM and cultured for 24 hours. A 1:1000 dilution of DCFH-DA was pre-prepared, the liquid was discarded, and after loading the probe, the 96-well plate was placed in an incubator and incubated for 40 minutes. The plate was then washed with PBS four times, each for 3 minutes. After replacing the PBS, the signal value at 495 nm was detected using a microplate reader. The results are shown in Figure 7.
[0129] Effect Example 4 Molecule 1 Anti-apoptosis Experiment
[0130] Logarithmically growing HaCaT cells were seeded into black-edged, transparent-bottomed well plates to a volume of 2 × 10 cells per well. 4 Cells were cultured in a complete culture medium (4.5 ml FBS (Sigma-F8318) + 45 ml MEM basal medium (gibco-C11095500BT) + 0.5 ml penicillin-streptomycin solution (Biosharp-BL505A)) in a carbon dioxide incubator at 37°C and 5% CO2 for 24 hours. The old culture medium was discarded, and 100 μL of HEPES was added to each well. The plate was moved under the UVB device and irradiated with 45 mJ. The control group (i.e., blank untreated) and the model group (UVB irradiation group) discarded the liquid and replaced with blank basal medium. The other wells were added with basal medium containing molecule 1. The compound doses were 40 μM and 80 μM, respectively. The control substance was palmitoyl pentapeptide (0.002 wt% and 0.008 wt% (reference concentrations in the literature, referred to as "ZLXWT" in the figure) and cultured for 24 hours. The cells were washed with PBS twice for 3 minutes each time, then fixed with paraformaldehyde for 30 minutes, washed with PBS three times for 3 minutes each time, blocked with BSA for 1 hour, incubated with Hochest dye for 30 minutes, washed with PBS three times for 3 minutes each time, and imaged and analyzed using the high-throughput cell imaging system of Perkin Elmer. The results are shown in Figures 8 and 9. At concentrations of 40 μM and 80 μM, the synthesized polypeptide significantly inhibited cell apoptosis and maintained cell viability compared with the Model group (P < 0.01), indicating that the anti-photoaging effect of the molecule 1 polypeptide is mainly to inhibit cell apoptosis.
[0131] Effect Example 5: Anti-collagen loss experiment
[0132] Logarithmically growing HaCaT cells were seeded into black-edged, transparent-bottomed well plates to a concentration of 2 x 10 cells per well. 4 Cells were cultured in a complete medium environment in a carbon dioxide incubator at 37°C and 5% CO2 for 24 hours. The old medium was discarded, and 100 μL of HEPES was added to each well. The plate was moved under a UVB device and irradiated with 45 mJ. The control group (i.e., blank untreated) and the model group (UVB irradiation group) were irradiated with the liquid and replaced with blank basal medium. The other wells were added with basal medium containing molecule 1. The compound doses were 4nM, 40nM, 400nM, 4μM, 40μM, and 400μM, respectively. The control substance was Type I porcine collagen (Jiafen Jiaoyuan, doses were 4nM, 40nM, 400nM, 4μM, 40μM, and 100μM, referred to as "Type I" in the figure) and cultured for 24 hours. The cells were washed twice with PBS for 3 minutes each time, then fixed with paraformaldehyde for 30 minutes, washed three times with PBS for 3 minutes each time, blocked with BSA for 1 hour, and incubated with type I collagen / type III collagen / fibronectin antibodies at 4°C overnight. The next day, the cells were washed three times with PBS for 3 minutes each time, incubated with Alex 488 and Hochest dye for 30 minutes, washed three times with PBS for 3 minutes each time, and imaged and analyzed using the Perkin Elmer high-throughput cell imaging system.
[0133] As shown in Figures 10 and 11, compound 25 is molecule 1. Compared with the Model group, the molecule 1 polypeptide significantly inhibited cell apoptosis and promoted collagen expression (P < 0.01). Compared with the control, molecule 1 was better than Type I collagen in promoting type I collagen expression at 40 μM, and still maintained good activity and cell viability at 40 μM, and its safety was better than Type I collagen.
[0134] As shown in Figures 12 and 13, compound 25 is molecule 1. Compared with the Model group, the synthesized molecule 1 significantly inhibited cell apoptosis and promoted collagen expression (P < 0.05). Compared with the control, molecule 1 at 40 μM promoted type III collagen expression better than Type I collagen, promoted cell viability, and had better safety than Type I collagen.
[0135] As shown in Figures 14 and 15, compound 25 is molecule 1. Compared with the Model group, the synthesized molecule 1 significantly inhibited cell apoptosis and promoted fibronectin expression (P < 0.05). Compared with the control, molecule 1 was better than Type I collagen in promoting fibronectin expression at 4 μM, and still maintained high activity and cell viability at 40 μM, and its safety was much better than Type I collagen.
[0136] Conclusion: In the anti-collagen loss experiment, both molecule 1 and Type I were tested for three indicators: collagen I, collagen type III and fibronectin. The test results showed that both molecule 1 and Type I have the effect of reducing the loss of collagen I, collagen type III and fibronectin, and molecule 1 is better than Type I.
[0137] Effect Example 6: Anti-wrinkle Experiment of Molecule 1
[0138] Zebrafish skin structure is similar to that of humans. Excessive ultraviolet (UV) exposure can lead to a decrease in collagen and elastin in the skin, manifesting as wrinkling of the caudal fin. After adding molecule 1, the change in caudal fin area after UV exposure was measured and the inhibition rate of caudal fin wrinkling was calculated. This allowed analysis of the extent to which molecule 1 protected zebrafish caudal fin deformation and, therefore, its anti-wrinkle efficacy was evaluated. Zebrafish were randomly selected and plated in 6-well plates, with 15 fish per well. The water-soluble sample was administered at a concentration of 0.0163% of the culture medium mass. A normal control group and a model control group were also set up, with a volume of 3 mL per well. After incubation at 28°C in the dark for 2 hours, all zebrafish in the normal control group, except the normal control group, were irradiated with UV light three times, each for 15 minutes, with 30 minutes between exposures, for a total irradiation dose of 6.21±0.54 J / cm². Incubation continued at 28°C in the dark for 22 hours. Ten zebrafish were randomly selected from each experimental group and photographed under a dissecting microscope. The photographs are shown in Figure 16. Advanced image processing software was used to analyze and collect data. The zebrafish tail fin area (A) was analyzed and the anti-wrinkle efficacy of the sample was calculated according to the formula to determine whether it had anti-wrinkle efficacy. The calculation formula is as follows:
[0139] The results are shown in FIG16 , where oligopeptide-625 amide is molecule 1. Compared with the model control group, the tail fin area of zebrafish treated with molecule 1 increased significantly, and the anti-wrinkle efficacy was about 30%.
[0140] Effect Example 7: Anti-inflammatory and soothing experiment of molecule 1
[0141] Sodium lauryl sulfate (SLS) may cause an irritation reaction in the body after it acts on the body. The irritant enters the zebrafish body, induces an inflammatory reaction, and neutrophils produce an immune response, migrating to the skin epidermis and gathering. IL-6 can promote the upregulation of neutrophil function, promote and regulate the secretion of inflammatory mediators such as cytokines, adhesion molecules, and nitric oxide. Sodium lauryl sulfate (SLS) may cause an irritation reaction in the body after it acts on the body. The irritant enters the zebrafish body, induces an inflammatory reaction, and neutrophils produce an immune response, migrating to the skin epidermis and gathering. IL-6 can promote the upregulation of neutrophil function, promote and regulate the secretion of inflammatory mediators such as cytokines, adhesion molecules, and nitric oxide. Using β-actin as an internal reference for gene expression, the relative RNA expression of the target gene was calculated. The results are shown in Table 3. The relative expression of the IL-6 gene in the experimental group was significantly downregulated compared with that in the model control group, revealing that the sample has a soothing effect.
[0142] Table 3 Relative expression of IL-6 gene
[0143] Based on the data from the above examples, it was determined that polypeptides of type 1 exhibit antioxidant properties, low toxicity, and reduced loss of collagen I, collagen type III, and fibronectin. Such molecules can be used in pharmaceuticals or cosmetics for cell anti-photoaging, pharmaceuticals or cosmetics (skin care products) for cell repair, or cell culture matrices, pharmaceuticals or cosmetics (skin care products) for promoting cell collagen production, or cell culture matrices, and products for tissue regeneration and repair of skin damaged by photoaging.
[0144] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A peptide compound, and a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, characterized in that: The amino acid sequence of the peptide compound is selected from one of the following: (1) The amino acid sequence shown in Formula I: XX1-XX2-XX3-XX4-XX5-XX6-XX7-XX8-XX9-XX10 (I); (2) having no more than 5, 4, 3, 2 or 1 amino acid difference from the amino acid sequence of Formula I; (3) a sequence having at least 80% identity to the amino acid sequence of Formula I; (4) is a variant of the amino acid sequence shown in Formula I, wherein the difference between the variant and the amino acid sequence shown in Formula I includes substitution, deletion and / or insertion of one or more amino acid residues or at least one N- / C-terminal extension.
2. The peptide compound according to claim 1, and its pharmaceutically acceptable salt, stereoisomer, solvate, characterized in that: In the amino acid sequence shown in Formula I, XX1 is selected from Tyr, Phe, Trp, D-Tyr, D-Trp or D-Phe; XX2 is selected from Leu, Ile, Gly, Aib, Met, Ala, Pro, D-Pro, D-Leu, D-Ile, D-Gly, D-Met or D-Ala; XX3 is selected from Ser, Thr, Cys, D-Ser, D-Thr or D-Cys; XX4 is selected from Ser, Thr, Cys, D-Ser, D-Thr or D-Cys; XX5 is selected from Leu, Ile, Gly, Aib, Met, Ala, Pro, D-Pro, D-Leu, D-Ile, D-Gly, D-Met or D-Ala; XX6 is selected from Asp, Asn, Glu, Gln, D-Asp, D-Asn, D-Glu or D-Gln; XX7 is selected from Leu, Ile, Gly, Aib, Met, Ala, Pro, D-Pro, D-Leu, D-Ile, D-Gly, D-Met or D-Ala; XX8 is selected from Cys, Met, D-Cys or D-Met; XX9 is selected from Leu, Ile, Gly, Aib, Met, Ala, Pro, D-Pro, D-Leu, D-Ile, D-Gly, D-Met or D-Ala; XX10 is selected from Cys, Met, D-Cys or D-Met.
3. The peptide compound according to claim 1, characterized in that The amino acid sequence of the peptide compound represented by formula I is shown in molecule 1: Molecule 1: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2.
4. The peptide compound according to claim 3, characterized in that The amino acid sequence of the peptide compound is the sequence shown in molecule 1, or a sequence that differs from molecule 1 by no more than two amino acids; Molecule 1: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2.
5. The peptide compound according to any one of claims 1 to 4, and its pharmaceutically acceptable salt, stereoisomer, solvate, characterized in that: The peptide compound XX1 has an amino group at its end, or the amino group forms an amide bond with an acetyl group, a formyl group or a methylsulfonyl group.
6. The peptide compound according to any one of claims 1 to 4, and its pharmaceutically acceptable salt, stereoisomer, solvate, characterized in that: The XX10 end of the peptide compound is a carboxyl group, or the carboxyl group is condensed with an amine compound to form an amide bond.
7. The peptide compound according to claim 6, and its pharmaceutically acceptable salt, stereoisomer, solvate, characterized in that: The amine compound is selected from NH3, MeNH2, Me2NH, EtNH2, and Et2NH.
8. The peptide compound according to claim 1, and its pharmaceutically acceptable salt, stereoisomer, solvate, characterized in that: The amino group of the amino acid in the peptide compound may be substituted by a C1-C4 alkyl group, and the C1-C4 alkyl group is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
9. The peptide compound according to claim 1, and its pharmaceutically acceptable salt, stereoisomer, solvate, characterized in that: The structures of the peptide compounds are as follows: Molecule 1: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2; Molecule 2: H-Phe-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2; Molecule 3: H-Trp-Ile-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2; Molecule 4: H-Trp-Leu-Cys-Thr-Pro-Glu-Pro-Met-Pro-Met-NH2; Molecule 5: H-Trp-Leu-Ser-Cys-Pro-Glu-Pro-Met-Pro-Met-NH2; Molecule 6: H-Trp-Leu-Ser-Thr-Pro-Asp-Pro-Met-Pro-Met-NH2; Molecule 7: H-Trp-Leu-Ser-Thr-Pro-Glu-Gly-Met-Pro-Met-NH2; Molecule 8: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Cys-Pro-Met-NH2; Molecule 9: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Ala-Met-NH2; Molecule 10: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Cys-NH2; Molecule 11: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH; Molecule 12: H-Phe-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH; Molecule 13: H-Trp-Ile-Ser-Thr-Pro-Glu-Pro-Met-Pro-Met-OH; Molecule 14: H-Trp-Leu-Cys-Thr-Pro-Glu-Pro-Met-Pro-Met-OH; Molecule 15: H-Trp-Leu-Ser-Cys-Pro-Glu-Pro-Met-Pro-Met-OH; Molecule 16: H-Trp-Leu-Ser-Thr-Pro-Asp-Pro-Met-Pro-Met-OH; Molecule 17: H-Trp-Leu-Ser-Thr-Pro-Glu-Gly-Met-Pro-Met-OH; Molecule 18: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Cys-Pro-Met-OH; Molecule 19: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Ala-Met-OH;Molecule 20: H-Trp-Leu-Ser-Thr-Pro-Glu-Pro-Met-Pro-Cys-OH. ; 10. A composition comprising the peptide compound according to any one of claims 1 to 7, and pharmaceutically acceptable salts, stereoisomers, and solvates thereof.
11. The composition according to claim 10, characterized in that The composition also includes pharmaceutically acceptable excipients.
12. Use of a peptide compound as claimed in any one of claims 1 to 9, and a pharmaceutically acceptable salt, stereoisomer, solvate thereof, and a composition as claimed in any one of claims 10 to 11 in the preparation of medicines and / or cosmetics, wherein the medicines and / or cosmetics have at least one of the following effects: whitening, inhibiting melanin production, removing spots, fading spots, anti-wrinkle, anti-aging, anti-photoaging, moisturizing, anti-inflammatory, anti-oxidation, tissue regeneration and repair after skin photodamage, promoting collagen synthesis, cell repair, and promoting cell adhesion.
Citation Information
Patent Citations
Decapeptide and application thereof
CN105153282A
Antioxidant decapeptide as well as preparation method and application thereof
CN114763370A
Novel synthetic peptides and cosmetic or pharmaceutical compositions and uses thereof
CN115583988A
Peptide with anti-aging effect as well as cosmetic composition or pharmaceutical composition and application thereof
CN115594735A
Peptide compound, composition and application thereof
CN117247427A
